BeiGene Takes Different Path In Seeking $100m US IPO
This article was originally published in PharmAsia News
Two well recognized Chinese biopharma companies, BeiGene and Hutchison China MediTech, have recently filed for initial public offerings of American Depositary Shares on the US Nasdaq market, with the aim of becoming integrated companies able to tap global markets. Both see good reasons for pursuing a path different to other Chinese peers that have recently delisted in the US.
Register for our free email digests: